International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

Amit G. Singal; Yujin Hoshida; David J. Pinato; Jorge Marrero; Jean Charles Nault; Valerie Paradis; Nabihah Tayob; Morris Sherman; Young Suk Lim; Ziding Feng; Anna S. Lok; Jo Ann Rinaudo; Sudhir Srivastava; Josep M. Llovet; Augusto Villanueva

doi:10.1053/j.gastro.2021.01.233

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

Amit G. Singal, Yujin Hoshida, David J. Pinato, Jorge Marrero, Jean Charles Nault, Valerie Paradis, Nabihah Tayob, Morris Sherman, Young Suk Lim, Ziding Feng, Anna S. Lok, Jo Ann Rinaudo, Sudhir Srivastava, Josep M. Llovet, Augusto Villanueva

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Original language	English (US)
Pages (from-to)	2572-2584
Number of pages	13
Journal	Gastroenterology
Volume	160
Issue number	7
DOIs	https://doi.org/10.1053/j.gastro.2021.01.233
State	Published - Jun 2021

Keywords

Biomarkers
Cirrhosis
Liver Cancer

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1053/j.gastro.2021.01.233

Cite this

Singal, A. G., Hoshida, Y., Pinato, D. J., Marrero, J., Nault, J. C., Paradis, V., Tayob, N., Sherman, M., Lim, Y. S., Feng, Z., Lok, A. S., Rinaudo, J. A., Srivastava, S., Llovet, J. M., & Villanueva, A. (2021). International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 160(7), 2572-2584. https://doi.org/10.1053/j.gastro.2021.01.233

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. / Singal, Amit G.; Hoshida, Yujin; Pinato, David J.; Marrero, Jorge; Nault, Jean Charles; Paradis, Valerie; Tayob, Nabihah; Sherman, Morris; Lim, Young Suk; Feng, Ziding; Lok, Anna S.; Rinaudo, Jo Ann; Srivastava, Sudhir; Llovet, Josep M.; Villanueva, Augusto.

In: Gastroenterology, Vol. 160, No. 7, 06.2021, p. 2572-2584.

Research output: Contribution to journal › Article › peer-review

Singal, AG , Hoshida, Y, Pinato, DJ, Marrero, J, Nault, JC, Paradis, V, Tayob, N, Sherman, M, Lim, YS, Feng, Z, Lok, AS, Rinaudo, JA, Srivastava, S, Llovet, JM & Villanueva, A 2021, 'International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma', Gastroenterology, vol. 160, no. 7, pp. 2572-2584. https://doi.org/10.1053/j.gastro.2021.01.233

Singal, Amit G. ; Hoshida, Yujin ; Pinato, David J. ; Marrero, Jorge ; Nault, Jean Charles ; Paradis, Valerie ; Tayob, Nabihah ; Sherman, Morris ; Lim, Young Suk ; Feng, Ziding ; Lok, Anna S. ; Rinaudo, Jo Ann ; Srivastava, Sudhir ; Llovet, Josep M. ; Villanueva, Augusto. / International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. In: Gastroenterology. 2021 ; Vol. 160, No. 7. pp. 2572-2584.

@article{13c728133597426d8313429d1dd528b3,

title = "International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma",

keywords = "Biomarkers, Cirrhosis, Liver Cancer",

author = "Singal, {Amit G.} and Yujin Hoshida and Pinato, {David J.} and Jorge Marrero and Nault, {Jean Charles} and Valerie Paradis and Nabihah Tayob and Morris Sherman and Lim, {Young Suk} and Ziding Feng and Lok, {Anna S.} and Rinaudo, {Jo Ann} and Sudhir Srivastava and Llovet, {Josep M.} and Augusto Villanueva",

note = "Funding Information: Conflict of interest Amit G. Singal has served as a consultant for Wako Diagnostics, Glycotest, Exact Sciences, Roche, GRAIL, Genentech, Bayer, Eisai, Exelixis, AstraZeneca, BMS, and TARGET Pharmasolutions. Yujin Hoshida has served as advisory board member for Helio Health, consultant for Ferring Pharmaceuticals, research funding from Morphic Therapeutics, and shareholder of Alentis Therapeutics. David J. Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. Jorge Marrero has served as a consultant for Glycotest. Jean-Charles Nault received a research grant from Bayer for Inserm UMR1148. Young Suk Lim is an advisory board member of Bayer Healthcare and Gilead Sciences and received investigator-initiated research funding from Bayer Healthcare and Gilead Sciences. Ziding Feng received research funding from Exact Sciences. Anna S. Lok serves on the advisory board of Epigenomics. Josep Llovet receives research support from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Eisai Inc, and Ipsen; and received consulting fees from AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Can-Fite Biopharma, Celsion Corporation, Eli Lilly, Eisai Inc, Exelixis, Genentech, Glycotest, Merck, Nucleix, and Roche. Augusto Villanueva receives consulting fees from Guidepoint, Fujifilm, Boehringer Ingelheim, FirstWord, and MHLife Sciences; advisory board fees from Exact Sciences, Nucleix, Gilead, and NGM Pharmaceuticals; and research support from Eisai. The remaining authors disclose no conflicts. Funding Information: Funding Amit G. Singal{\textquoteright}s research is supported in part by National Cancer Institute U01 CA230694 , R01 CA222900 , and U01 CA226052 . Yujin Hoshida{\textquoteright}s research is supported by the National Institutes of Health (NIH) ( CA233794 , CA226052 ), European Commission ( ERC-2014-AdG-671231 ), Cancer Prevention and Research Institute of Texas ( RR180016 ). David J. Pinato is supported by the Wellcome Trust Strategic Fund ( PS3416 ), Cancer Research UK (Postdoctoral Bursary Grant C57701/A26137 ), and the Conquer Cancer, the ASCO Foundation (Young Investigator Award 2019) and acknowledges infrastructural support by the Cancer Research UK Imperial Centre and the Experimental Cancer Medicine Centre. Ziding Feng is supported in part by NIH U24CA230144 and U24CA086368. Nabihah Tayob is supported in part by NIH R01CA230503, U24CA230144, R01CA222900, and U01CA230694. Anna S. Lok is supported in part by NIH U01CA230669 and R01CA230503. Josep Llovet. acknowledges funding from the Accelerator Award (CRUCK, AEEC, AIRC) (HUNTER, Ref. C9380/A26813), National Cancer Institute (P30-CA196521), US Department of Defense (CA150272P3), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (PID2019-105378RB-100), and the Generalitat de Catalunya/AGAUR (SGR-1358). Augusto Villanueva is supported by the US Department of Defense (CA150272). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funding agency had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation of the manuscript. ",

year = "2021",

month = jun,

doi = "10.1053/j.gastro.2021.01.233",

language = "English (US)",

volume = "160",

pages = "2572--2584",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "7",

}

TY - JOUR

T1 - International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

AU - Singal, Amit G.

AU - Hoshida, Yujin

AU - Pinato, David J.

AU - Marrero, Jorge

AU - Nault, Jean Charles

AU - Paradis, Valerie

AU - Tayob, Nabihah

AU - Sherman, Morris

AU - Lim, Young Suk

AU - Feng, Ziding

AU - Lok, Anna S.

AU - Rinaudo, Jo Ann

AU - Srivastava, Sudhir

AU - Llovet, Josep M.

AU - Villanueva, Augusto

N1 - Funding Information: Conflict of interest Amit G. Singal has served as a consultant for Wako Diagnostics, Glycotest, Exact Sciences, Roche, GRAIL, Genentech, Bayer, Eisai, Exelixis, AstraZeneca, BMS, and TARGET Pharmasolutions. Yujin Hoshida has served as advisory board member for Helio Health, consultant for Ferring Pharmaceuticals, research funding from Morphic Therapeutics, and shareholder of Alentis Therapeutics. David J. Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. Jorge Marrero has served as a consultant for Glycotest. Jean-Charles Nault received a research grant from Bayer for Inserm UMR1148. Young Suk Lim is an advisory board member of Bayer Healthcare and Gilead Sciences and received investigator-initiated research funding from Bayer Healthcare and Gilead Sciences. Ziding Feng received research funding from Exact Sciences. Anna S. Lok serves on the advisory board of Epigenomics. Josep Llovet receives research support from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Eisai Inc, and Ipsen; and received consulting fees from AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Can-Fite Biopharma, Celsion Corporation, Eli Lilly, Eisai Inc, Exelixis, Genentech, Glycotest, Merck, Nucleix, and Roche. Augusto Villanueva receives consulting fees from Guidepoint, Fujifilm, Boehringer Ingelheim, FirstWord, and MHLife Sciences; advisory board fees from Exact Sciences, Nucleix, Gilead, and NGM Pharmaceuticals; and research support from Eisai. The remaining authors disclose no conflicts. Funding Information: Funding Amit G. Singal’s research is supported in part by National Cancer Institute U01 CA230694 , R01 CA222900 , and U01 CA226052 . Yujin Hoshida’s research is supported by the National Institutes of Health (NIH) ( CA233794 , CA226052 ), European Commission ( ERC-2014-AdG-671231 ), Cancer Prevention and Research Institute of Texas ( RR180016 ). David J. Pinato is supported by the Wellcome Trust Strategic Fund ( PS3416 ), Cancer Research UK (Postdoctoral Bursary Grant C57701/A26137 ), and the Conquer Cancer, the ASCO Foundation (Young Investigator Award 2019) and acknowledges infrastructural support by the Cancer Research UK Imperial Centre and the Experimental Cancer Medicine Centre. Ziding Feng is supported in part by NIH U24CA230144 and U24CA086368. Nabihah Tayob is supported in part by NIH R01CA230503, U24CA230144, R01CA222900, and U01CA230694. Anna S. Lok is supported in part by NIH U01CA230669 and R01CA230503. Josep Llovet. acknowledges funding from the Accelerator Award (CRUCK, AEEC, AIRC) (HUNTER, Ref. C9380/A26813), National Cancer Institute (P30-CA196521), US Department of Defense (CA150272P3), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (PID2019-105378RB-100), and the Generalitat de Catalunya/AGAUR (SGR-1358). Augusto Villanueva is supported by the US Department of Defense (CA150272). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funding agency had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation of the manuscript.

PY - 2021/6

Y1 - 2021/6

KW - Biomarkers

KW - Cirrhosis

KW - Liver Cancer

UR - http://www.scopus.com/inward/record.url?scp=85106905932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106905932&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.01.233

DO - 10.1053/j.gastro.2021.01.233

M3 - Article

C2 - 33705745

AN - SCOPUS:85106905932

VL - 160

SP - 2572

EP - 2584

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 7

ER -

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this